文献速递类风湿关节炎

开发预测模型以选择患有合并症的老年类风湿关节炎患者接受慢性低剂量糖皮质激素治疗

Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

在GLORIA研究中,451例≥65岁类风湿关节炎患者随机接受2年泼尼松龙5 mg/日或安慰剂。基于基线变量开发8个预测模型(4个不考虑治疗、4个考虑低剂量泼尼松龙),分别预测危害(AESIs发生及每年AESIs数量)与获益(早期临床应答/疾病活动度、无关节破坏进展)。少数变量略有预测性但无立即临床价值,模型性能低至中等(解释方差12-15%,AUC 0.67-0.69)。结论认为基线因素因预测获益或危害的能力低,无助于选择老年RA患者接受低剂量泼尼松龙治疗。

要点

  • 在451例≥65岁RA合并症患者中开发8个预测模型,分别预测危害与获益结局。
  • 模型性能低至中等:解释方差12-15%,AUC 0.67-0.69。
  • 基线因素预测获益或危害的能力低,无助于选择患者接受低剂量泼尼松龙治疗。

核心结论

  • 基线因素因预测获益或危害的能力低,无助于选择老年RA患者接受低剂量泼尼松龙治疗。

研究设计与样本

  • 基于GLORIA研究数据,451例≥65岁RA合并症患者随机接受2年泼尼松龙5 mg/日或安慰剂。
  • 采用逐步法基于先验知识开发8个预测模型,4个不考虑研究治疗、4个考虑低剂量泼尼松龙附加作用。
  • 每个模型集中2个聚焦危害(AESIs发生及每年AESIs数量)、2个聚焦获益(早期临床应答/疾病活动度、无关节破坏进展)。
  • 采用线性与逻辑多变量回归及向后选择法开发模型,最终模型用自举法评估与内部验证。

主要发现

  • 少数变量对模型中某一结局略有预测性,但均无立即临床价值。
  • 预测模型质量足够,性能低至中等(解释方差12-15%,AUC 0.67-0.69)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 预测模型性能低至中等(解释方差12-15%,AUC 0.67-0.69)。
  • 基线因素预测获益或危害的能力低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop prediction models for individual patient harm and benefit outcomes in elderly patients with RA and comorbidities treated with chronic low-dose glucocorticoid therapy or placebo. METHODS: In the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) study, 451 RA patients ≥65 years of age were randomized to 2 years 5 mg/day prednisolone or placebo. Eight prediction models were developed from the dataset in a stepwise procedure based on prior knowledge. The first set of four models disregarded study treatment and examined general predictive factors. The second set of four models was similar but examined the additional role of low-dose prednisolone. In each set, two models focused on harm [the occurrence of one or more adverse events of special interest (AESIs) and the number of AESIs per year) and two on benefit (early clinical response/disease activity and a lack of joint damage progression). Linear and logistic multivariable regression methods with backward selection were used to develop the models. The final models were assessed and internally validated with bootstrapping techniques. RESULTS: A few variables were slightly predictive for one of the outcomes in the models, but none were of immediate clinical value. The quality of the prediction models was sufficient and the performance was low to moderate (explained variance 12-15%, area under the curve 0.67-0.69). CONCLUSION: Baseline factors are not helpful in selecting elderly RA patients for treatment with low-dose prednisolone given their low power to predict the chance of benefit or harm. TRIAL REGISTRATION: https://clinicaltrials.gov; NCT02585258.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hartman L, da Silva JAP, Buttgereit F, et al. Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids. Rheumatology (Oxford). 2023. PMID: 36165675. doi:10.1093/rheumatology/keac547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。